MedTrace Logo

The Development of a Metabolomic Test to Diagnose and Quantify Pancreatic Exocrine Insufficiency (The DETECTION Study)

NCT05980221 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-08-07

No results posted yet for this study

Summary

DETECTION. The development of a metabolomic test to diagnose and quantify pancreatic exocrine insufficiency.

Conditions

  • Pancreatic Exocrine Insufficiency

Interventions

DIAGNOSTIC_TEST

Metabolomics

Plasma samples taken for the investigation of the metabolome

DIAGNOSTIC_TEST

13C MTGT

sequential breath samples taken for investigation of PEI (reference test)

Sponsors & Collaborators

  • Pancreatic Cancer UK

    collaborator OTHER

  • University Hospital Birmingham NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Keith Roberts, PhD · University Hospital Birmingham NHS Foundation Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-24
Primary Completion
2024-10-31
Completion
2024-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05980221 on ClinicalTrials.gov